211 results
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
prex” i je ber’ sen), which targets growth factor receptor-bound protein 2 (Grb2), initially started the efficacy portion of a Phase 2 clinical trial … second drug candidate, Liposomal Bcl-2 (“BP1002”), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
9:17am
), which targets growth factor receptor-bound protein 2 (Grb2), initially started the efficacy portion of a Phase 2 clinical trial for untreated acute … , Liposomal Bcl-2 (“BP1002”), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. On November 21, 2019
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
18 Apr 24
Other Events
9:13am
of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options.”
BP1002 targets the protein Bcl-2, which is responsible … is venetoclax, an oral Bcl-2 inhibitor that targets the BH3 domain of the Bcl-2 protein, in combination with a hypomethylating agent or with low-dose
8-K
EX-99.1
pnx9nxv f0pec
15 Apr 24
Bio-Path Holdings Expands Global Patent Portfolio
7:30am
8-K
EX-10.1
j2uyv0hvgoye79b7
4 Apr 24
Entry into a Material Definitive Agreement
4:35pm
424B5
t1w5 q2z9yfej
4 Apr 24
Prospectus supplement for primary offering
4:33pm
8-K
EX-99.1
zr3juqyz j1ssqtmvk
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
424B5
2pc4t4
27 Mar 24
Prospectus supplement for primary offering
8:15am
8-K
EX-99.1
6u10fjgcj 3x7dlfepo
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
EX-99.1
o1v51 xvn1wxx25t
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
EX-99.1
vs50 icqa
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
EX-99.1
wsqvui74yusp7lkmp98
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am